02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 373 BOARD OF LICENSURE 392 MAINE BOARD OF IN MEDICINE PHARMACY Chapter 5 Chapter 39 Collaborative DRUG THERAPY MANAGEMENT Summary: This is a joint rule of the Board of Licensure in Medicine and the Board of Pharmacy for purposes of establishing safe and effective collaborative practice agreements, treatment protocols, and documentation and reporting requirements between a pharmacist and a practitioner. Acknowledgment. The Boards recognize that the Maine Legislature enacted 2013 Public Law Chapter 308 to allow collaborative practice agreements between authorized practitioners and pharmacists and to expand access to healthcare while ensuring that all patients receive the most appropriate healthcare possible and to provide safe and efficient care to the citizens of Maine. 1. Definitions 1. Board. For purposes of the Maine Board of Pharmacy. this chapter, “Board” means 2. drug therapy is Collaborative drug therapy management. “Collaborative management” defined in 32 MRS §13702-A(2-A). The statutory requirements for collaborative drug therapy management are set forth in 32 MRS §§ 13841-13847. 3. Collaborative practice agreement. practice is defined in “Collaborative agreement” 32 MRS §13702-A(2-B). 4. Practitioner. is defined in 32 MRS §13702-A(29). “Practitioner” 5. Qualifying condition. means a condition or disease with “Qualifying condition” generally accepted standards of care, which may include, but is not limited to, the following examples: A. Anticoagulation B. Asthma C. Diabetes D. Dyslipidemia E. Hyperlipidemia F. Hypertension G. Infectious Disease
02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 373 BOARD OF LICENSURE IN MEDICINE Chapter 5 392 MAINE BOARD OF PHARMACY Chapter 39 Collaborative DRUG THERAPY MANAGEMENT Summary: This is a joint rule of the Board of Licensure in Medicine and the Board of Pharmacy for purposes of establishing safe and effective collaborative practice agreements, treatment protocols, and documentation and reporting requirements between a pharmacist and a practitioner. Acknowledgment. The Boards recognize that the Maine Legislature enacted 2013 Public Law Chapter 308 to allow collaborative practice agreements between authorized practitioners and pharmacists and to expand access to healthcare while ensuring that all patients receive the most appropriate healthcare possible and to provide safe and efficient care to the citizens of Maine. 1. Definitions 1. Board. For purposes of this chapter, “Board” means the Maine Board of Pharmacy. 2. Collaborative drug therapy management. “Collaborative drug therapy management” is defined in 32 MRS §13702-A(2-A). The statutory requirements for collaborative drug therapy management are set forth in 32 MRS §§ 13841-13847. 3. Collaborative practice agreement. “Collaborative practice agreement” is defined in 32 MRS §13702-A(2-B). 4. Practitioner. “Practitioner” is defined in 32 MRS §13702-A(29). 5. Qualifying condition. “Qualifying condition” means a condition or disease with generally accepted standards of care, which may include, but is not limited to, the following examples: A. Anticoagulation B. Asthma C. Diabetes D. Dyslipidemia E. Hyperlipidemia F. Hypertension G. Infectious Disease
373c005.docx